Acurx Pharmaceuticals Inc...

0.73
-0.05 (-6.05%)
At close: Jan 29, 2025, 3:59 PM
0.73
0.68%
After-hours Jan 29, 2025, 05:25 PM EST

Company Description

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.

Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.

The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae.

Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc. logo
Country United States
IPO Date Jun 25, 2021
Industry Biotechnology
Sector Healthcare
Employees 4
CEO David P. Luci CPA, Esq., J.D.

Contact Details

Address:
259 Liberty Avenue
Staten Island, New York
United States
Website https://www.acurxpharma.com

Stock Details

Ticker Symbol ACXP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001736243
CUSIP Number 00510M104
ISIN Number US00510M1045
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
David P. Luci CPA, Esq., J.D. Co-Founder, President, Chief Executive Officer, Corporate Secretary & Director
Robert G. Shawah CPA, CPA Co-Founder & Chief Financial Officer
Robert J. DeLuccia Co-Founder & Executive Chairman

Latest SEC Filings

Date Type Title
Jan 17, 2025 D Filing
Jan 08, 2025 4 Filing
Jan 08, 2025 4 Filing
Jan 08, 2025 4 Filing
Jan 08, 2025 4 Filing
Jan 08, 2025 4 Filing
Jan 08, 2025 4 Filing
Jan 07, 2025 424B5 Filing
Jan 07, 2025 8-K Current Report
Jan 06, 2025 424B3 Filing